- Category
- pharma
- Made by
- Helix Biotech
- Tier
- Silver
Overview
NeuroSmooth is the daily neural-interface stabilizer Helix Pharma supplies to most high-grade cybernetic patients in the Sprawl. The product is administered as a single capsule per day from a surgical-white pharmaceutical dispenser, and its function is, in Helix's clinical literature, to "complete the unfinished signal between cybernetic implant and biological brain." Most cybernetic interface manufacturers list NeuroSmooth as the standard-of-care compatibility cofactor in their device specifications. The reason is that Helix supplies most of the chrome those manufacturers integrate, and Helix supplies the stabilizer, and the loop, in board minutes, is called elegant.
The product is single-source by Sprawl pharmaceutical statute Section 47.3. No generic is permitted. Helix's stated reason is the PHARMA precedent: the eighty-five million dead from compound substitution errors made it impossible to permit generic neural-interface pharmaceuticals at any quality tier. The bandwidth limits hardcoded into all NeuroSmooth-paired interfaces descend from MENTOR survivor neural damage data acquired in the Seoul Aftershock — the brand has not advertised this lineage, but Sauer's files contain the citation. The 99.7% retention rate is reported internally as patient confidence and externally as standard of care; the two phrasings, by design, do not contradict.
Packaging & Appearance
A surgical-white pharmaceutical capsule dispenser with the Helix double-helix embossed prominently in deep green on the side, and a single capsule visible through a soft-cyan dosing window at the front. The neural-handshake antenna at the dispensing port brightens when the patient's biometric profile is recognized and dims after the dose is dispensed. The casing is rounded, soft-touch, and sized for the gloved hand of the pharmacist at the Helix Clinic counter; that is the canonical handhold. The label carries regulatory text in three font sizes and a QR code that links, exclusively, to a credentialed-clinician NDA portal.
Ingredients
Helix Bandwidth Matrix v3.0 (proprietary; full composition disclosed only to credentialed clinicians under NDA — neural signal stabilizers, interface bandwidth cofactors, MENTOR-derivative compounds at safe dosages). Neural-handshake activation (single-use, ingestion-grade). Compliance telemetry (passive, continuous, ninety-day retention). Quarterly regimen subscription with automatic renewal. Single-source by Sprawl pharmaceutical statute Section 47.3.
What Nobody Can Explain
Unverified · in-world intelligence
The MENTOR survivor data used to set bandwidth ceilings has never been published. Sauer's files contain a citation. The underlying dataset is listed as restricted under Seoul Aftershock remediation protocols. No independent researcher has accessed it. Helix has not acknowledged it exists.
Compliance telemetry routes to insurers. Helix describes the routing logic as proprietary. What the insurers do with ninety days of continuous neural-interface behavioral data, beyond premium adjustment, has not been disclosed. The insurers have not been asked publicly.
Three independent pharmaceutical research groups applied for Section 47.3 exemptions to develop generic neural-interface stabilizers in the last decade. All three applications were denied by the Sprawl Pharmaceutical Authority. Two of the three research leads subsequently accepted positions at Helix. The third is not locatable.
The 0.3% who cancel — and survive the taper — are not in the patient outcome database Helix publishes. Helix says they are tracked under a separate discontinued-use registry. The registry has not been made available to external auditors.
Marketing
